Pancreatic Cancer Research

ResearcherChampalimaud FoundationActive in the last 2 years

Markus Wolfgang Büchler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3666-5675; OpenAlex author ID A5036032282. Sources: OpenAlex.

Their work

Papers
180 (first author 28, last author 41)
Trials
0
Grants
0
Labs led
2
Collaborators
406
Papers, trials and grants by year

2011: 10 papers · 2012: 12 papers · 2013: 16 papers · 2014: 10 papers · 2015: 7 papers · 2016: 12 papers · 2017: 14 papers · 2018: 8 papers · 2019: 14 papers · 2020: 12 papers · 2021: 16 papers · 2022: 13 papers · 2023: 17 papers · 2024: 6 papers · 2025: 5 papers · 2026: 8 papers

Papers 50 of 180

  1. Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2026.04.007↗
  2. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00601-1↗
  3. Pancreatic Cancer Frequently Infiltrates the TRIANGLE Compartment: A Surgical Option to Prevent Local Recurrence. Last author DOI 10.1097/as9.0000000000000672↗
  4. Preoperative Surgical or Endoscopic Bile Duct Drainage in Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000006407↗
  5. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  6. The Role of Circulating Tumor DNA in Surgical Management of Pancreatic Cancer: Systematic Review and Meta-analysis. Last author DOI 10.1097/sla.0000000000007036↗
  7. Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19264-2↗
  8. Blood-based prediction and early detection of pancreatic cancer recurrence after tumor resection Co-author DOI 10.20892/j.issn.2095-3941.2025.0495↗
  9. Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adeno… Co-author DOI 10.1002/ueg2.12676↗
  10. GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. Co-author DOI 10.1016/j.esmogo.2025.100138↗
  11. Radical antegrade modular pancreatosplenectomy versus conventional left pancreatectomy for pancreatic cancer: study protocol for the multicentre randomized cli… Co-author DOI 10.1093/bjsopen/zraf169↗
  12. Editor's Note: Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-4286↗
  13. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y↗
  14. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  15. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166↗
  16. Total versus Partial Pancreatectomy in Patients with Pancreatic Cancer Arising from Multifocal or Diffuse Intraductal Papillary Mucinous Neoplasia - A Multicen… Co-author DOI 10.1097/sla.0000000000006538↗
  17. Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. Co-author DOI 10.1111/jgh.16686↗
  18. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  19. Intraoperative end-tidal carbon dioxide levels are not associated with recurrence-free survival after elective pancreatic cancer surgery: a retrospective cohor… Co-author DOI 10.3389/fmed.2024.1442283↗
  20. Structural expression of bovine milk and meat factors in tissues of colorectal, lung and pancreatic cancer patients. Co-author DOI 10.1002/ijc.34374↗
  21. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  22. Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection of IPMN-associated pancreatic adenocarcin… Co-author DOI 10.1016/j.ejso.2022.08.003↗
  23. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  24. Neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.1038/s41571-023-00746-1↗
  25. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Co-author DOI 10.1038/s43018-023-00628-6↗
  26. Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.05.036↗
  27. Influence of beta-blockers and other non-cancer drugs on outcomes after pancreatic cancer resection. Co-author DOI 10.1093/bjs/znac434↗
  28. Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival. Co-author DOI 10.1093/function/zqad011↗
  29. Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival. Last author DOI 10.1097/sla.0000000000005444↗
  30. Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005481↗
  31. Distal Pancreatectomy With En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer: A Safe and Effective Procedure. Last author DOI 10.1097/sla.0000000000005866↗
  32. DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma. Co-author DOI 10.1136/gutjnl-2023-330155↗
  33. Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer. First author DOI 10.1200/jco.23.00779↗
  34. Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis. Co-author DOI 10.1245/s10434-022-12569-y↗
  35. Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. Co-author DOI 10.1245/s10434-022-12901-6↗
  36. Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. Co-author DOI 10.3389/fcell.2023.1179559↗
  37. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  38. [Locally advanced pancreatic cancer after FOLFIRINOX: surgical resection enhances survival]. First author DOI 10.1007/s00104-021-01558-8↗
  39. A histopathological study of artery wall involvement in pancreatic cancer surgery. Co-author DOI 10.1007/s00423-022-02689-0↗
  40. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade. Co-author DOI 10.1016/j.ejso.2021.07.020↗
  41. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy. Co-author DOI 10.1016/j.ejso.2021.12.009↗
  42. [Evidence for Neoadjuvant Therapy in Resectable Pancreatic Cancer]. First author DOI 10.1055/a-1775-8924↗
  43. Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis. Co-author DOI 10.1093/bjsopen/zrac010↗
  44. Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve. Last author DOI 10.1097/sla.0000000000004054↗
  45. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  46. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Last author DOI 10.1097/sla.0000000000004147↗
  47. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004845↗
  48. Resection of Recurrent Pancreatic Cancer: Who Can Benefit? First author DOI 10.1159/000519754↗
  49. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. Co-author DOI 10.1186/s13046-022-02519-7↗
  50. Neoadjuvant Chemotherapy in Pancreatic Cancer. First author DOI 10.1001/jamasurg.2020.6273↗

Closest collaborators

The 25 strongest of 406 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thilo Hackert · 83 shared papers, 2011–2026 · strength 9.86
  2. Oliver Strobel · 64 shared papers, 2011–2026 · strength 7.20
  3. John P. Neoptolemos · 45 shared papers, 2011–2026 · strength 4.67
  4. Thomas P. Hank · 21 shared papers, 2015–2026 · strength 3.16
  5. Martin Loos · 16 shared papers, 2012–2026 · strength 2.92
  6. Christoph Springfeld · 18 shared papers, 2013–2026 · strength 2.44
  7. Ulla Klaiber · 16 shared papers, 2019–2023 · strength 2.18
  8. Martin A. Schneider · 10 shared papers, 2020–2026 · strength 1.97
  9. Ingmar Florin Rompen · 8 shared papers, 2024–2026 · strength 1.74
  10. Benedict Kinny‐Köster · 9 shared papers, 2023–2026 · strength 1.64
  11. Christoph W. Michalski · 10 shared papers, 2016–2026 · strength 1.45
  12. Jörg Kaiser · 10 shared papers, 2017–2025 · strength 1.39
  13. Nathalia A. Giese · 19 shared papers, 2011–2025 · strength 1.38
  14. Mohammed Al‐Saeedi · 6 shared papers, 2022–2026 · strength 1.30
  15. Markus K. Diener · 10 shared papers, 2013–2025 · strength 1.26
  16. Marc G. Besselink · 8 shared papers, 2019–2026 · strength 1.24
  17. Joseph R. Habib · 7 shared papers, 2023–2026 · strength 1.24
  18. Jens Werner · 29 shared papers, 2011–2020 · strength 1.11
  19. Paula Ghaneh · 14 shared papers, 2014–2025 · strength 1.11
  20. André L. Mihaljević · 9 shared papers, 2017–2023 · strength 1.09
  21. Peter J. Bailey · 6 shared papers, 2021–2026 · strength 1.08
  22. Lois A. Daamen · 6 shared papers, 2024–2026 · strength 1.07
  23. Izaak Quintus Molenaar · 6 shared papers, 2024–2026 · strength 1.07
  24. Ammar A. Javed · 6 shared papers, 2024–2026 · strength 1.07
  25. Christopher Michael Halloran · 13 shared papers, 2014–2025 · strength 1.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.